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Abstract 
Hypoxic circumstances result in functional and structural impairments of the brain. Oxygen-
glucose deprivation (OGD) on hippocampal slices is a technique widely used to investigate 
the consequences of ischemic stroke and the potential neuroprotective effects of different 
drugs. Acetyl-L-carnitine (ALC) is a naturally occurring substance in the body, and it can 
therefore be administered safely even in relatively high doses. In previous experiments, ALC 
pretreatment proved to be effective against global hypoperfusion. In the present study, we 
investigated whether ALC can be protective in an OGD model. We are not aware of any 
earlier study in which the long-term potentiation (LTP) function on hippocampal slices was 
measured after OGD. Therefore, we set out to determine whether an effective ALC 
concentration has an effect on synaptic plasticity after OGD in the hippocampal CA1 subfield. 
A further aim was to investigate the mechanism underlying the protective effect of this 
compound. The experiments revealed that ALC is neuroprotective against OGD in a dose-
dependent manner, which is manifested not only in the regeneration of the impaired synaptic 
transmission after the OGD, but also in the inducibility and stability of the LTP. In the case of 
the most effective concentration of ALC (500 µM), use of a phosphoinositide 3-kinase (PI3K) 
inhibitor (LY294002) revealed that the PI3K/Akt signaling pathway has a key role in the 
restoration of the synaptic transmission and plasticity reached by ALC treatment.  
Keywords: oxygen-glucose deprivation, acetyl-L-carnitine, long-term potentiation, PI3K/Akt, 
neuroprotection, ischemia
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1. Introduction 
Cerebral ischemia results in failure of the bioenergetic processes. The key element of this 
phenomenon is the breakdown of the mitochondria, which leads to the failure of ATP 
production and the excessive release of Ca2+. It causes not only excitotoxicity, but also the 
generation of reactive oxygen species, the release of proapoptotic signal proteins and the 
subsequent neuronal death (Ten and Starkov 2012). It has been well established that the 
hippocampus, and especially the CA1 subfield, is extremely sensitive to hypoxic-
hypoglycemic conditions (Kirino 1982, Pulsinelli et al. 1982), which can occur, for example, 
during ischemic stroke or cardiac arrest. Hippocampal slices are widely used to investigate the 
injury induced by ischemic events and to measure the effects of different pharmacological 
interventions against the neuronal damage (Picconi et al. 2006, Molz et al. 2015). Oxygen-
glucose deprivation (OGD) mimicking brain ischemia can result in the reversible or 
irreversible depression of neurotransmission, depending on the duration of this insult.  
Electrophysiological recordings from slice preparations allow continuous monitoring of the 
changes in the evoked electrical responses which can occur as a result of the ischemic event 
or potential neuroprotective agents (Picconi et al. 2006, Nistico et al. 2008). Furthermore, the 
hippocampus is a suitable and generally used model system for the study of synaptic 
plasticity, and especially long-term potentiation (LTP), since it is involved in learning and 
memory (Ho et al. 2011). As a result of the vulnerability to hypoxic-hypoglycemic 
circumstances of this structure, the effects of ischemia are manifested in functional and 
morphological damages, e.g. LTP impairment and the loss of dendritic spines (Kocsis et al. 
2014), or in irreversible harmful processess ending in cell death. 
Acetyl-L-carnitine (ALC) is an endogenous compound, which is a short-chain acetyl ester of 
L-carnitine (Bremer 1983, Bieber 1988) synthesized in the human brain, liver and kidney by 
the enzyme ALC transferase.  This molecule affects the overall energy metabolism and cell 
functions, including the regulation of the lipid, carbohydrate and protein metabolism 
(Rapoport 1999), it boosts mitochondrial ATP production and it protects the mitochondria 
against oxidative stress (Zanelli et al. 2005). ALC is actively transported across the blood-
brain barrier to the brain (Burlina et al. 1989), where it has a relative high concentration (Shug 
et al. 1982). Several studies have demonstrated the neuroprotective effect of ALC against 
different neurodegenerative diseases, such as Alzheimer’s disease, ischemia or neuropathic 
pain (Di Cesare Mannelli et al. 2009, Zhou et al. 2011, Xu et al. 2015). We previously 
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investigated the neuroprotective effect of ALC against global hypoperfusion in a 2-vessel 
occlusion (2VO) model (Kocsis et al. 2014, Kocsis et al. 2015). The effects of ALC were also 
tested on striatal slices in an in vitro ischemia model, where it prevented the loss of the 
recorded field excitatory postynaptic potentials (fEPSPs) through the activation of M2 
muscarinic receptors and the choline uptake system (Picconi et al. 2006). Moreover, the 
mechanisms underlying the neuroprotective effect of ALC exhibit a great deal of variety, 
since it provides a substrate reservoir for cellular energy production, facilitates the uptake of 
acetyl-CoA into the mitochondria during fatty acid oxidation, enhances different synthesis 
processes (Fiskum 2004, Di Cesare Mannelli et al. 2010), has antioxidant and anti-apoptotic 
properties (Zanelli et al., 2005), and induces nerve regeneration by increasing the production 
and binding of the nerve growth factor (Foreman et al. 1995).  
In the present study, our aim was to examine the potential neuroprotective effect of ALC 
against in vitro global ischemia delivered to hippocampal slices. To the best of our 
knowledge, there has not been any study so far in which the LTP function was measured on a 
hippocampal slice after OGD. We therefore set out to determine whether an effective ALC 
concentration has an effect on synaptic plasticity after OGD in the hippocampal CA1 subfield. 
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2. Experimental procedures 
2.1 Animals and housing conditions 
Male Wistar rats weighing 200-250 g (N = 21) supplied by Charles River Laboratories, were 
kept under constant environmental conditions (23 °C; humidity 55 ± 5%; a 12-h/12-h 
light/dark cycle) and were housed individually in standard plastic cages, where they had free 
access to food and water. Every effort was made to minimize the number of animals used and 
their suffering. The principles of animal care (NIH publication No. 85-23), and the protocol 
for animal care approved both by the Hungarian Health Committee (1998) and by the 
European Communities Council Directive (2010/63/EU) were followed. Before the 
experimental procedures, all the rats were in normal health and had no neurogical deficits.  
2.2. In vitro slice preparation 
The preparation and maintenance of rat hippocampal slices were described previously (Kocsis 
et al., 2014; Kocsis et al., 2015). Briefly, the animals were decapitated and the middle parts of 
the hippocampi were placed in ice-cold artificial cerebrospinal fluid (aCSF) composed of (in 
mM): 130 NaCl, 3.5 KCl, 1 NaH2PO4, 24 NaHCO3, 1 CaCl2, 3 MgSO4 and 10 D-glucose (all 
from Sigma, Germany), saturated with 95% O2 + 5% CO2. Coronal hippocampal slices (350 
μm) were prepared with a vibratome (Leica VT1200S, Germany). Slices were transferred to a 
holding chamber and allowed to recover in the solution used for recording (differing only in 
that it contained 3 mM CaCl2 and 1.5 mM MgSO4) for at least 1 h.  
 
2.3. Electrophysiological recordings 
For the electrophysiological experiments, slices were transferred to a Haas recording 
chamber, where the flow rate of the recording solution (34 °C) was 1.5–2 ml×min−1.  A 
bipolar concentric stainless steel electrode (Neuronelektrod Ltd, Hungary) was placed in the 
stratum radiatum between the CA1 and CA2 regions of the hippocampal slices. The stimulus 
intensity was adjusted to between 30 and 60 µA (constant current, 0.2-ms pulses delivered at 
0.05 Hz) to evoke the half-maximum response. fEPSPs were recorded with a 1.5-2.5 MΩ 
resistance glass micropipette filled with aCSF. The recordings were amplified with a 
neutralized, high input-impedance preamplifier and filtered (1 Hz-3 kHz). The fEPSPs were 
digitized (AIF-03, Experimetria Ltd. Hungary), acquired at a sampling rate of 10 kHz, saved 
to a PC and analyzed off-line with Origin Pro 8 software (OriginLab Corporation, 
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Northampton, MA, USA). The fEPSPs were monitored until the amplitudes were generally 
stable, and a 10-min-long baseline was then recorded, which was followed by a 15-min OGD. 
The fEPSPs were allowed to recover for 40 min after the OGD, and at the end of this period 
theta burst stimulation (TBS) was applied (bursts of 4 impulses at 100 Hz with a burst interval 
of 350 ms) for LTP measurements. After the TBS, changes in fEPSP amplitudes were 
recorded for a further 35 min (Fig. 1). 
 
2.4. In vitro ischemia 
In vitro ischemia was delivered by switching for 15 min to an OGD aCSF solution in which 
sucrose replaced glucose, and gassed with 95% N2 + 5% CO2. After the OGD, the slices were 
perfused with normal aCSF again until the end of the measurements. In the preliminary 
experiments, OGD was delivered for different periods (5, 8, 12, 15, 16, and 17 min) in order 
to determine the appropriate length of the ischemia for our study. After shorter terms of OGD, 
the fEPSPs returned, but the aim was to find the limit when the fEPSPs no longer displayed 
recovery. Electrical noise could not be excluded completely during the electrophysiological 
measurements, and it also was present after the elimination of the fEPSPs. This is the reason 
why the recorded amplitudes never reached the value of zero. Both fEPSP amplitudes and 
initial slopes were recorded and quantified in all of the measurements; however as no 
appreciable differences between these two parameters were observed, only the amplitudes are 
expressed in the figures. 
2.5. Application of ALC 
ALC (Sigma, Germany) was applied for 25 min at the desired final concentration (125, 250 or 
500 μM) in aCSF or OGD aCSF for the control (10 min) and the OGD period (15 min), 
respectively. In the preliminary studies, ALC was tested in all of the concentrations utilized in 
the further experiments (25-min wash-in), and none of them influenced the amplitudes (Fig. 
3). Nevertheless, all the recordings also were self-controlled, since after the stabilization of 
the fEPSPs, the recordings started with a 10-min period when the slices were still perfused 
with normal aCSF solution. This was followed by an additional 10 min, when the aCSF 
contained ALC. Since no differences were still observed, this ALC wash-in period was 
regarded as the control baseline during the data analysis. The wash-in of the ALC was 
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continued during the 15-min OGD, and it was then followed by the recovery period when 
normal aCSF solution was perfused onto the slices (Fig. 1).  
2.6. Application of LY294002 
In order to investigate the mechanisms underlying the protective effect of ALC, a 
phosphoinositide 3-kinase (PI3K) inhibitor, LY294002 (Tocris, United Kingdom) was 
utilized, in a final concentration of 50 µM. It was dissolved in aCSF or OGD aCSF containing 
500 µM ALC, and the solution was washed onto the slices during the control and the OGD 
period, respectively.  
2.7. Statistical analysis 
In OGD measurements, the fEPSP amplitudes were expressed as a percentage of the 10-min 
baseline value before OGD, while to express the potentiation after LTP induction the last 10 
min of the recovery period following the OGD was regarded as a baseline.  
For data presented as means ± S.E.M., statistical analysis was performed with the use of the 
non-parametric Wilcoxon test and the Mann-Whitney U test. The significance level was 
established at p < 0.05. 
 
3. Results 
In the first part of the experiments, our aim was to determine the accurate duration of OGD 
sufficient for the elimination of the fEPSPs. After shorter OGD periods (5 min or 8 min), the 
amplitudes displayed a complete recovery. In the case of the 5-min OGD, the fEPSPs 
demonstrated not only regeneration after the ischemia, but also facilitation (presumably post-
ischemic LTP). The increased amplitudes were stable until the end of the recording period. A 
12-min period of ischemia was likewise not enough to abolish the fEPSPs, but 16 or 17-min 
periods of OGD resulted in complete elimination of the amplitudes (Fig. 2). A 15-min period 
of OGD (N = 9) was the shortest which abolished the fEPSPs, and the following experiments 
were carried out with this model. A slight increase of the fEPSPs was detected immediately 
after the OGD in almost all measurements of the different experimental groups, and the 
amplitudes started to decrease only thereafter. This phenomenon is probably due to an 
increased sensitivity of the potsynaptic NMDA receptors due to the removal of Mg2+ ions 
from the ionophore part during an ischemic event, an excitotoxic circumstance that may have 
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resulted first in an abnormal facilitation of the synaptic transmission in the CA1 region, and 
then by the progression of OGD lead to the complete elimination of the fEPSPs. 
The potential neuroprotective effect of ALC against 15-min OGD was tested in different 
concentrations. Based on our preliminary studies, we chose 125, 250, and 500 µM ALC for 
the OGD measurements. Before these experiments, the potential neuromodulatory effect of 
ALC was tested on control slices. None of the applied concentrations influenced the fEPSPs 
(Fig. 3).  
125 µM ALC was ineffective in half of the group (N = 6), while in the other half of the 
experiments (N = 6) it resulted in a slight recovery. Increase of the fEPSPs after OGD was 
slow and reached its maximum early. The average of the amplitudes in the last 10 min of the 
recordings was significantly lower (58.91 ± 3.70%) as compared with the control level. As a 
result of 250 µM ALC (N = 12), the fEPSPs increased continuously and reached the control 
level within 25 min. In the last 10 min of the recording period, the amplitudes stabilized at a 
significantly higher level (107.59 ± 2.37%) relative to the control. 500 µM ALC (N = 12) 
resulted in an even faster recovery of the fEPSPs. There was no significant difference between 
the values for the last 10 min of the 250 and 500 µM ALC groups, but both were significantly 
higher than that for the 125 µM ALC group (Fig. 4). 
After the 40-min recovery period, LTP was induced by TBS and the fEPSP amplitudes were 
measured for an additional 35 min. The level of the LTPs was normalized to the last 10 min of 
the recovery period. The LTP inducibility was tested in the 15-min OGD group, but because 
of the irreversible elimination of the fEPSPs, no potentiation was observed. The illustration of 
these results in Fig. 5 was therefore not adequate. From the 6 samples showing partial 
restoration in the 125 µM ALC group, we observed LTP in only 2 cases. The fEPSPs showed 
a weak potentiation in the first 10 min after TBS (116.87 ± 1.62%), then started to decrease 
and at the end of the recordings they had fallen back to the control level (102.79 ± 0.96%). 
There was no significant difference between the control period and the last 10 min of the 
recording. 250 µM ALC (N = 12) resulted in a higher potentiation, although the amplitudes 
showed a slight decrease for 15 min after TBS and stabilized only thereafter (123.96 ± 
1.97%). This potentiation was significantly higher as compared with the values for the 125 
µM ALC group. 500 µM (N = 12) was the most effective ALC concentration since it resulted 
not only in complete restoration of the fEPSPs after OGD, but also in a stable LTP. As a 
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result of the TBS, the amplitudes increased, stabilized immediately and remained stable until 
the end of the recording period (141.12 ± 0.90%). This LTP is similar to that of tested in 
control conditions (140.75 ± 0.40%) on hippocampal slices (N = 8). In the 500 µM ALC-
treated group, the average of the fEPSP amplitudes in the last 10 minutes of the recordings 
was significantly higher relative to the control level and to the values of the last 10 min of the 
125 and 250 µM ALC groups (Fig. 5).  
LY294002, a PI3K inhibitor, was used to reveal the mechanisms underlying the protective 
effect of ALC, which was manifested in the recovery of the fEPSPs and a stable LTP after 
OGD. As a result of 500 µM ALC, the amplitudes started to decrease later during the 
ischemia as compared with the OGD group, but this effect was abolished in the presence of 
the inhibitor (N = 8). After the OGD period, the fEPSPs did not recover when ALC was 
applied with LY294002 (Fig. 6). LTP inducibility was also tested in the group that received 
500 µM ALC + LY294002, but the complete and irreversible elimination of the fEPSPs 
resulted in the same results as recorded in the 15-min OGD group. Fig. 7 shows representative 
traces from the different experimental groups. There were no pathological responses to the 
stimulation none of the cases, even after the TBS. 
 
4. Discussion 
Hypoxic conditions, reperfusion and reoxygenization are central elements of many disorders 
in the nervous system, e.g. ischemic stroke, traumatic brain injury and heart attack (Ronaldson 
and Davis 2013). During an ischemic event, the limited blood flow in different parts or in the 
whole brain results in a complex cascade of molecular processes, which leads to cell death 
(Thompson and Ronaldson 2014). There is still no effective solution with which to prevent 
the structural and functional impairments of stroke patients, and it is therefore very important 
to search for alternative treatments which could rescue the nerve tissue. ALC is a naturally 
occurring substance which has been demonstrated to be neuroprotective in different diseases 
(Malaguarnera 2012). ALC is widely distributed in the tissues; its synthesis occurs in the 
brain, intestine, liver and kidney (Pettegrew et al. 2000). The therapeutic application of this 
compound is promising since it readily crosses the blood-brain barrier, affects many 
bioenergetic processes, exhibits antioxidant, antiapoptotic and neuromodulatory effects and 
enhances nerve regeneration (Jones et al. 2010). Among the numerous mechanisms 
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underlying the neuroprotective action of ALC, it is likely that this nutrient can serve as an 
alternative source of acetyl-CoA during or after cerebral ischemia. ALC enhances the aerobic 
energy metabolism impaired by the breakdown of the pyruvate dehydrogenase complex under 
hypoxic conditions (Zanelli et al. 2005).  
In previous experiments, we investigated the potential neuroprotective action of ALC against 
global hypoperfusion in a 2VO model of rats. We found that ALC was effective only when it 
was administered before the ischemic insult, but not as post-treatment (Kocsis et al., 2014). 
These findings are in accordance with the results of other research groups. In the present 
study, we examined the effect of this compound against in vitro global ischemia on 
hippocampal brain slices with electrophysiological techniques. Our aim was not only to find 
the effective concentration of ALC which restores the synaptic transmisson after OGD, but 
also to measure the LTP function after the recovery period.  
After determination of the accurate period of OGD sufficient for the elimination of the 
fEPSPs, we tested ALC in different concentrations as pretreatment. In preliminary studies, 
ALC applied after OGD did not have protective effect, which was in accordance with a 
previous report (Picconi et al., 2006). Hence, the compound was washed into the slices before 
and during the OGD period.  
Though 15-min OGD resulted in the complete elimination of fEPSPs, which was not followed 
by recovery, there might be differences between each slice as regards the extent of the 
damage or the number of the potentially salvageable neurons, which may underlie the results 
revealed in the 125 µM ALC-treated group. Indeed, this concentration was high enough in 
some cases to achieve a detectable slight neuroprotective effect, probably corresponding to 
slices with a higher number of salvageable neurons remained following the 15-min OGD. The 
ineffectiveness of 125 µM ALC in the other half of the experiments suggests that this 
concentration may be in the edge of the least effective concentration of ALC in this model. 
The damages caused by OGD to the neuronal network of the hippocampal CA1 subfield could 
be partially restored with 125 µM ALC only at the level of fEPSPs, but not at that of a 
complex process such as LTP. Nevertheless, in 2 cases of the 125 µM ALC group, we 
detected a slight and decaying potentiation. These results, similarly to the partial restoration of 
the fEPSPs, may also be accounted for the potential differences in the status of the particular 
slices exposed to ischemia. 
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250 and 500 µM ALC displayed similar protective effects in the recovery period, but we 
found differences between the LTP results of these groups. Despite the complete recovery in 
the 250 µM ALC group, the pontentiation of the fEPSP amplitudes was not stable after TBS. 
500 µM ALC exerted its neuroprotective effect via the restoration of the fEPSPs and also 
preservation of the synaptic integrity and plasticity.  
The PI3K/protein kinase B (Akt) pathway is important during the development of the central 
nervous system and plays a critical role in mediating survival signals in a wide range of 
circumstances (Brunet et al. 2001). Furthermore, it has been well established that this 
signaling pathway mediates synaptic plasticity and memory (Horwood et al. 2006), and is also 
involved in the cognitive impairment caused by chronic cerebral hypoperfusion (Shu et al. 
2013).  
Among several mechanisms through which ALC exerts its protective action, the importance 
of the PI3K/Akt pathway has already been demonstrated. In cortical neuronal cell cultures 
exposed to oxidative stress-induced neurodegeneration, ALC and α-lipoic acid pretreatment 
resulted in activation of the PI3K, PKG and ERK1/2 pathways, which have essential roles in 
cell survival (Abdul and Butterfield 2007). In the present study, we explored the hypothesis 
that ALC exerts its neuroprotective effect via the PI3K/Akt pathway, which is manifested not 
only in the recovery of the fEPSPs after OGD, but also in the potentiation of the amplitudes 
after TBS. Despite the complete recovery and stable LTP reached following 500 µM ALC 
treatment, LY294002 administration abolished this protective effect.  
These results suggest that the PI3K/Akt pathway is necessary for the neuroprotection induced 
by ALC in different ways. This ALC-activated signaling pathway promotes cell survival 
mechanisms through which the synaptic transmission recovers after OGD. Additionally, 
activation of the PI3K/Akt pathway contributes to the enhancement of the synaptic plasticity 
revealed by the LTP measurements. Nevertheless, there are many other mechanisms 
connected with the neuroprotective effect of ALC, which can simultaneously take part in the 
results revealed in our experiments.  
Among the various beneficial effects of ALC, its natural presence in the body underlies the 
feasibility of this compound in patients with high safety. Experiments measuring the potential 
protective effect of ALC in different animal models of diseases are promising and provide a 
broad range of information for clinical research. Clinical trials with ALC in patients have so 
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far rather focused on neurodegenerative diseases (e.g. Alzheimer’s disease); however, the 
numerous studies revealing its neuroprotective effects in ischemic models emphasize the 
importance of the assessment of the neuroprotective efficacy of ALC also in clinical trials of 
stroke as well in the future. 
 
5. Conclusions  
In this study, we demonstrated that ALC can exert its protective effect on a complex process 
such as LTP, a phenomenon underlying the basis of learning and memory, which provides 
further relevance of its therapeutic application. Overall, these results also contribute to the 
better understanding of the relationship between ALC and the neuroprotection following 
ischemia. 
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8. Legends to Figures 
Fig. 1 
Schematic timeline of the experimental protocol. ALC was washed onto the slices during the 
10-min control and the 15-min OGD period. At the end of the recovery period, LTP was 
induced by TBS. The last 10 min of the recovery period (symbolized by the gray part of the 
black line) was regarded as the control baseline of the LTP period. 
 
Fig. 2 
Results of the preliminary experiments conducted to determine the sufficient period of OGD. 
5-min OGD resulted in complete recovery of the fEPSPs (N = 2). In some cases, a noteworthy 
facilitation was observed after the 5-min OGD (N = 2), which was presumably a post-
ischemic LTP. The 8- and 12-min OGD were still not enough to eliminate the fEPSPs; these 
periods resulted in complete or partial regeneration, respectively (N = 2 and 4, respectively). 
Longer OGD periods (16 min (N = 2) and 17 min (N = 2)) completely abolished the fEPSPs. 
Data points are means ± S.E.M. of the normalized amplitudes of the fEPSPs. 
 
Fig. 3 
The potential neuromodulatory effect of 125 (N = 6), 250 (N = 6), and 500 µM ALC (N = 6) 
was tested on control hippocampal slices (25-min-long ALC application). None of the 
concentrations influenced the fEPSPs. Data points are means ± S.E.M. of the normalized 
amplitudes of the fEPSPs. 
 
Fig. 4 
ALC was neuroprotective against 15-min OGD in a dose-dependent manner. The 15-min 
OGD (N = 9) was the shortest period which was not followed by any recovery, and ALC was 
therefore tested in this model. 125 µM ALC resulted in a slight recovery in only half of the 
group (N = 6), but in the other half (N = 6) it was ineffective. 250 and 500 µM ALC (N = 12 
each) were protective: the fEPSPs recovered completely after the OGD. Data points are 
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means ± S.E.M. of the normalized amplitudes of the fEPSPs. Asterisks denote significant 
differences between the control and the last 10 min of the recovery period (**p < 0.01, ***p < 
0.001, Wilcoxon test), # denotes significant differences between the last 10 min of the 
recovery period of each experimental group ( ### p < 0.001, n.s.: not significant; Mann-
Whitney U test). 
 
Fig. 5 
The effect of ALC on LTP inducibility. Despite the slight regeneration of the fESPSs in the 
125 µM ALC group, LTP could be induced in only 2 cases. The potentiation was weak, and 
the amplitudes started to decrease immediately, and reached the control baseline at the end of 
the recordings. 250 µM ALC (N = 12) resulted in a significantly higher LTP, but showed a 
slight decrease for 15 min after TBS and stabilized only thereafter. 500 µM ALC (N = 12) 
was the most effective concentration. It was manifested in significant potentiation, which was 
stable over time. This LTP is similar to that of tested on hippocampal slices (N = 8) in control 
conditions (inset in the upper right quadrant). Data points are means ± S.E.M. of the 
normalized amplitudes of the fEPSPs. Asterisks denote significant differences between the 
control and the last 10 min of the LTP period (***p < 0.001, Wilcoxon test); # denotes 
significant differences between the last 10 min of the LTP period of each experimental group 
( ### p < 0.001, n.s.: not significant; Mann-Whitney U test). 
 
Fig. 6 
The PI3K/Akt pathway has a key role in the neuroprotective effect of ALC. The 15-min OGD 
(N = 9) completely eliminated the fEPSPs, which was blocked by 500 µM ALC (N = 12) 
treatment, but in the presence of LY294002 (N = 8) this protective effect of ALC was 
abolished. Data points are means ± S.E.M. of the normalized amplitudes of the fEPSPs. 
 
Fig. 7 
Representative traces of fEPSPs from the different experimental groups recorded in the 
control, the last 10 min of the recovery, and the last 10 min of the post-TBS period. 125 μM 
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ALC was effective against the ischemic insult in half of the experiments (N = 6), but only 2 of 
them showed a slight potentiation after TBS. This LTP was unstable and the amplitudes 
decreased to the pre-TBS level at the end of the recordings (3rd row). Both 250 and 500 μM of 
ALC resulted in a complete recovery of the fEPSPs; however, stable LTP could only be 
recorded in the 500 μM ALC-treated group. This effect of ALC was abolished in the presence 
of LY294002. 
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